



For Immediate Release

SENEXIS RECEIVES GRAD AWARD FROM EEDA TO SELECT A NOVEL ALZHEIMER'S DRUG

Cambridge, 27th August 2009 - Senexis Limited, a private drug development company, announced today that they have been awarded a Government grant to develop neuroinflammation inhibitors for the treatment of Alzheimer's disease. The Grant for Research and Development (GRAD) award from EEDA (East of England Development Agency) will help to expand and complement Senexis' growing pipeline of novel compounds for the treatment of other ageing-related diseases. The new funding will accelerate the discovery of novel compounds with the potential to treat the later stages of Alzheimer's disease.

"The GRAD award will enable us to select a molecule as a development candidate for subsequent progression into clinical trials" **said David Scopes, Senexis' Chief Scientific Officer**. "We believe that that the new funding will accelerate the development of novel compounds that inhibit the inappropriate inflammation of the brain that can be triggered by amyloid".

-Ends-

About Senexis

Senexis is a growing drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of Alzheimer's and other diseases and Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Further information on Senexis can be found at www.senexis.com.

About the East of England Development Agency

The East of England Development Agency (EEDA) is the driving force behind sustainable economic regeneration in the East of England: Bedfordshire, Cambridgeshire, Essex, Hertfordshire, Norfolk and Suffolk. The vision for the East of England is to create a leading economy, founded on a world class knowledge base, creativity and enterprise to improve the quality of life for all who live and work here. For further information visit www.eeda.org.uk

For further information, please contact:

Dr J. Mark Treherne, Chief Executive of Senexis on:

Tel.: 01223 496160

Fax.: 01223 496161